Format

Send to

Choose Destination
Front Pharmacol. 2014 Jun 4;5:128. doi: 10.3389/fphar.2014.00128. eCollection 2014.

Iron, hepcidin, and the metal connection.

Author information

1
INSERM UMR 991, Iron and the Liver Team Rennes, France ; Faculty of Medicine, University of Rennes1 Rennes, France ; CHU Pontchaillou, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital-Rennes Rennes, France.
2
INSERM UMR 991, Iron and the Liver Team Rennes, France ; Faculty of Medicine, University of Rennes1 Rennes, France ; Biochemistry and Enzymology Laboratory, Centre Hospitalier Universitaire Rennes, France.
3
INSERM UMR 991, Iron and the Liver Team Rennes, France ; Faculty of Medicine, University of Rennes1 Rennes, France ; Department of Rheumatology, Centre Hospitalier Universitaire Rennes, France.
4
INSERM UMR 991, Iron and the Liver Team Rennes, France ; CHU Pontchaillou, French Reference Centre for Rare Iron Overload Diseases of Genetic Origin, University Hospital-Rennes Rennes, France ; Biochemistry and Enzymology Laboratory, Centre Hospitalier Universitaire Rennes, France.

Abstract

Identification of new players in iron metabolism, such as hepcidin, which regulates ferroportin and divalent metal transporter 1 expression, has improved our knowledge of iron metabolism and iron-related diseases. However, from both experimental data and clinical findings, "iron-related proteins" appear to also be involved in the metabolism of other metals, especially divalent cations. Reports have demonstrated that some metals may affect, directly or indirectly, the expression of proteins involved in iron metabolism. Throughout their lives, individuals are exposed to various metals during personal and/or occupational activities. Therefore, better knowledge of the connections between iron and other metals could improve our understanding of iron-related diseases, especially the variability in phenotypic expression, as well as a variety of diseases in which iron metabolism is secondarily affected. Controlling the metabolism of other metals could represent a promising innovative therapeutic approach.

KEYWORDS:

DMT1; disease; ferroportin; iron; metabolism; metal; transferrin

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center